Fluvoxamine versus clomipramine for obsessive-compulsive disorder: A double-blind comparison

Lorrin M. Koran, Susan L. Mcelroy, Jonathan R T Davidson, Steven A. Rasmussen, Eric Hollander, Michael A. Jenike

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

The efficacy and tolerability of fluvoxamine (100-300 mg/day) and clomipramine (100-250 mg/day) were compared in a randomized, double-blind, parallel-group study of 79 patients with obsessive-compulsive disorder (OCD) without coexisting major depression. After a 2-week placebo lead-in period, patients were randomized to fluvoxamine (37 patients) or clomipramine (42 patients) for 10 weeks. Efficacy was evaluated with the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), the National Istitute of Mental Health Obsessive Compulsive scale, and Patient and Clinical Global Improvement scales. Hamilton Rating Scale for Depression scores and somatic symptoms were also assessed. Seventy-eight percent of fluvoxamine patients and 64% of clomipramine patients completed the study. At the end of treatment, 56% of fluvoxamine patients were classified as responders (225% decrease in Y-BOCS score), compared with 54% of clomipramine patients. Both groups showed steady improvement throughout the study; no statistically significant differences were observed between the groups for any efficacy variable at any time. A similar percentage of patients in both groups withdrew because of adverse events. No serious adverse events related to drug occurred with either drug. Insomnia, nervousness, and dyspepsia were more statistically frequent with fluvoxamine; dry mouth and postural hypotension were more frequent with clomipramine. In this study, fluvoxamine and clomipramine were equally effective in reducing OCD symptoms over a 10-week treatment period but displayed different side effect profiles.

Original languageEnglish (US)
Pages (from-to)121-129
Number of pages9
JournalJournal of Clinical Psychopharmacology
Volume16
Issue number2
DOIs
StatePublished - 1996
Externally publishedYes

Fingerprint

Fluvoxamine
Clomipramine
Obsessive-Compulsive Disorder
Depression
Orthostatic Hypotension
Dyspepsia
Sleep Initiation and Maintenance Disorders
Pharmaceutical Preparations
Mouth
Mental Health
Anxiety
Placebos

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Fluvoxamine versus clomipramine for obsessive-compulsive disorder : A double-blind comparison. / Koran, Lorrin M.; Mcelroy, Susan L.; Davidson, Jonathan R T; Rasmussen, Steven A.; Hollander, Eric; Jenike, Michael A.

In: Journal of Clinical Psychopharmacology, Vol. 16, No. 2, 1996, p. 121-129.

Research output: Contribution to journalArticle

Koran, Lorrin M. ; Mcelroy, Susan L. ; Davidson, Jonathan R T ; Rasmussen, Steven A. ; Hollander, Eric ; Jenike, Michael A. / Fluvoxamine versus clomipramine for obsessive-compulsive disorder : A double-blind comparison. In: Journal of Clinical Psychopharmacology. 1996 ; Vol. 16, No. 2. pp. 121-129.
@article{5e3feb679b06435e970c5197edcb2386,
title = "Fluvoxamine versus clomipramine for obsessive-compulsive disorder: A double-blind comparison",
abstract = "The efficacy and tolerability of fluvoxamine (100-300 mg/day) and clomipramine (100-250 mg/day) were compared in a randomized, double-blind, parallel-group study of 79 patients with obsessive-compulsive disorder (OCD) without coexisting major depression. After a 2-week placebo lead-in period, patients were randomized to fluvoxamine (37 patients) or clomipramine (42 patients) for 10 weeks. Efficacy was evaluated with the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), the National Istitute of Mental Health Obsessive Compulsive scale, and Patient and Clinical Global Improvement scales. Hamilton Rating Scale for Depression scores and somatic symptoms were also assessed. Seventy-eight percent of fluvoxamine patients and 64{\%} of clomipramine patients completed the study. At the end of treatment, 56{\%} of fluvoxamine patients were classified as responders (225{\%} decrease in Y-BOCS score), compared with 54{\%} of clomipramine patients. Both groups showed steady improvement throughout the study; no statistically significant differences were observed between the groups for any efficacy variable at any time. A similar percentage of patients in both groups withdrew because of adverse events. No serious adverse events related to drug occurred with either drug. Insomnia, nervousness, and dyspepsia were more statistically frequent with fluvoxamine; dry mouth and postural hypotension were more frequent with clomipramine. In this study, fluvoxamine and clomipramine were equally effective in reducing OCD symptoms over a 10-week treatment period but displayed different side effect profiles.",
author = "Koran, {Lorrin M.} and Mcelroy, {Susan L.} and Davidson, {Jonathan R T} and Rasmussen, {Steven A.} and Eric Hollander and Jenike, {Michael A.}",
year = "1996",
doi = "10.1097/00004714-199604000-00004",
language = "English (US)",
volume = "16",
pages = "121--129",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Fluvoxamine versus clomipramine for obsessive-compulsive disorder

T2 - A double-blind comparison

AU - Koran, Lorrin M.

AU - Mcelroy, Susan L.

AU - Davidson, Jonathan R T

AU - Rasmussen, Steven A.

AU - Hollander, Eric

AU - Jenike, Michael A.

PY - 1996

Y1 - 1996

N2 - The efficacy and tolerability of fluvoxamine (100-300 mg/day) and clomipramine (100-250 mg/day) were compared in a randomized, double-blind, parallel-group study of 79 patients with obsessive-compulsive disorder (OCD) without coexisting major depression. After a 2-week placebo lead-in period, patients were randomized to fluvoxamine (37 patients) or clomipramine (42 patients) for 10 weeks. Efficacy was evaluated with the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), the National Istitute of Mental Health Obsessive Compulsive scale, and Patient and Clinical Global Improvement scales. Hamilton Rating Scale for Depression scores and somatic symptoms were also assessed. Seventy-eight percent of fluvoxamine patients and 64% of clomipramine patients completed the study. At the end of treatment, 56% of fluvoxamine patients were classified as responders (225% decrease in Y-BOCS score), compared with 54% of clomipramine patients. Both groups showed steady improvement throughout the study; no statistically significant differences were observed between the groups for any efficacy variable at any time. A similar percentage of patients in both groups withdrew because of adverse events. No serious adverse events related to drug occurred with either drug. Insomnia, nervousness, and dyspepsia were more statistically frequent with fluvoxamine; dry mouth and postural hypotension were more frequent with clomipramine. In this study, fluvoxamine and clomipramine were equally effective in reducing OCD symptoms over a 10-week treatment period but displayed different side effect profiles.

AB - The efficacy and tolerability of fluvoxamine (100-300 mg/day) and clomipramine (100-250 mg/day) were compared in a randomized, double-blind, parallel-group study of 79 patients with obsessive-compulsive disorder (OCD) without coexisting major depression. After a 2-week placebo lead-in period, patients were randomized to fluvoxamine (37 patients) or clomipramine (42 patients) for 10 weeks. Efficacy was evaluated with the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), the National Istitute of Mental Health Obsessive Compulsive scale, and Patient and Clinical Global Improvement scales. Hamilton Rating Scale for Depression scores and somatic symptoms were also assessed. Seventy-eight percent of fluvoxamine patients and 64% of clomipramine patients completed the study. At the end of treatment, 56% of fluvoxamine patients were classified as responders (225% decrease in Y-BOCS score), compared with 54% of clomipramine patients. Both groups showed steady improvement throughout the study; no statistically significant differences were observed between the groups for any efficacy variable at any time. A similar percentage of patients in both groups withdrew because of adverse events. No serious adverse events related to drug occurred with either drug. Insomnia, nervousness, and dyspepsia were more statistically frequent with fluvoxamine; dry mouth and postural hypotension were more frequent with clomipramine. In this study, fluvoxamine and clomipramine were equally effective in reducing OCD symptoms over a 10-week treatment period but displayed different side effect profiles.

UR - http://www.scopus.com/inward/record.url?scp=0029947585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029947585&partnerID=8YFLogxK

U2 - 10.1097/00004714-199604000-00004

DO - 10.1097/00004714-199604000-00004

M3 - Article

C2 - 8690827

AN - SCOPUS:0029947585

VL - 16

SP - 121

EP - 129

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 2

ER -